Onconic Therapeutics

476060· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩12,650+12.54%

2026-08-04

Financials

Valuation Metrics

Onconic Therapeutics's Market Cap is ₩5744B. At end of 2025 it was ₩8877B. Ranked #414 of 2,436 in KR market (top 17%), #138 of 1,649 on KOSDAQ (top 8%), #47 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	574.41B KRW	KR#414/2,436 Sec#47/234
Revenue	67.20B KRW	KR#1,629/2,436 Sec#108/234
Net Income	20.33B KRW	KR#640/2,436 Sec#43/234
Total Assets	87.59B KRW	KR#1,847/2,436 Sec#150/234
Net Assets	79.52B KRW	KR#1,563/2,436 Sec#129/234
Value
P/E	28.26x	KR#1,234/2,436 Sec#73/234
P/B	7.22x	KR#2,300/2,436 Sec#196/234
PEG	0.12x	KR#410/2,436 Sec#23/234
P/S	8.55x	KR#2,250/2,436 Sec#157/234
EV/EBITDA	33.45x	KR#1,227/2,436 Sec#83/234
FCF Yield	1.93%	KR#1,077/2,436 Sec#73/234
Profitability
ROE	25.56%	KR#73/2,436 Sec#5/234
ROA	23.21%	KR#21/2,436 Sec#4/234
Op. Margin	23.25%	KR#107/2,436 Sec#16/234
Revenue Growth	150.64%	KR#91/2,436 Sec#15/234
Earnings Growth	241.90%	KR#212/2,436 Sec#14/234
Financial Health
Debt Ratio	110.14%	KR#439/2,436 Sec#63/234
Total Debt	0 KRW	KR—/2,436 Sec—/234
FCF	11.09B KRW	KR#687/2,436 Sec#39/234
Cash	51.77B KRW	KR#738/2,436 Sec#46/234
Current Ratio	9.48x	KR#112/2,436 Sec#29/234
Net Debt/EBITDA	-3.31x	KR#185/2,436 Sec#5/234
Performance
1Y Return	106.97%	KR#117/2,436 Sec#13/234
1M Return	0.08%	KR#873/2,436 Sec#76/234
From 52W High	-56.23%	KR#1,519/2,436 Sec#129/234
1Y MDD	-63.84%	KR#1,631/2,436 Sec#134/234
Trading
Volume	785,874 shares	KR#167/2,436 Sec#11/234
Foreign Own.	2.22%	KR#1,071/2,436 Sec#105/234
Per Share
EPS	458 KRW	KR#942/2,436 Sec#66/234
BPS	1,772 KRW	KR#2,094/2,436 Sec#175/234